Cadrenal Therapeutics, Inc. CVKD
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is a hematology drug developer. Its lead program, CAD-1005, is in Phase 2 for heparin-induced thrombocytopenia (HIT); also cardiac surgery-associated acute kidney injury. Its next catalyst on record is CAD-1005: NDA submission, contingent on obtaining funding to run the pivotal Phase 3 (2029).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CAD-1005 — NDA submission, contingent on obtaining funding to run the pivotal Phase 3 (2029). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CAD-1005 (12-LOX inhibitor) | HIT; CSA-AKI | small molecule | Phase 2 |
| tecarfarin | chronic anticoagulation in ESKD/AFib and LVAD patients; Kawasaki disease coronary aneurysms | small molecule | Phase 2 |
| frunexian | IV Factor XIa inhibitor anticoagulation in cardiac surgery | small molecule | Phase 1 |
| CAD-2000 | chronic cardiorenal inflammatory and thrombotic indications (oral 12-LOX inhibitor) | small molecule | Pre-clinical |
Recent results and decisions
- Jun 18, 2026n/a Company plans to submit a Rare Pediatric Disease Designation request to FDA for tecarfarin in pediatric Kawasaki disease.
today announced plans to submit a Rare Pediatric Disease Designation (RPDD) request to the U.S. Food and Drug Administration (FDA) for tecarfarin as a treatment for pediatric patients with Kawasaki disease (KD)
Filing - Apr 30, 2026n/a Completed FDA End-of-Phase 2 meeting; company plans to proceed directly to a randomized placebo-controlled Phase 3 with primary endpoint of new or worsening thrombotic events.
After considering FDA feedback on a pivotal registration study, Cadrenal plans to advance directly to a randomized, blinded, placebo-controlled Phase 3 study evaluating CAD-1005 added to the current standard of care for patients with HIT.
Filing - Feb 24, 2026missed Phase 2 (n=24) missed primary endpoint of platelet count recovery (similar to placebo); secondary thrombotic events 50% vs >75% on placebo, not powered for significance.
Although CAD-1005 did not significantly affect platelet recovery rate, CAD-1005-treated patients had fewer thrombotic events.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 hematology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.